Japan's newly developed anti-cancer drugs are in the research stage. Their application involves the formulation of injectable anti-cancer drugs, with the patent number 3PK83201995; EPAppl145174, EPAppl147175. In the development survey for SUN4800, T cells, PHA (plant hemagglutinin), and anti-lymphocyte globulin can cause irritation. The molecular weight is approximately 580,013,000. Initially, production and refining were costly due to the use of E. coli and yeast secretion of bacterial production outside, which helped reduce drug costs. A frozen dried preparation was used in clinical validation for skin cancer starting from June 1985. It is an ideal treatment for skin cancer and has now completed clinical validation, with applications for listing underway.
Si Drug BRL a 43 694 (graniselron) is in phase I clinical trials as an anti-cancer drug. The patent is GB10752 [CAS] 107007-99-8 [Chemical name] endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methylindazole-3-carboxamide. BRL-43694 strongly inhibits vomiting caused by anti-cancer drug delivery and has entered phase I clinical trials, soon to be applied for listing.
KM2210 (Kregtan) is under development by Kureha Chemical Industry. Its use is in capsule form as an anti-cancer drug [types], with the patent DEOften2932607 [CAS] 75219-46-4 [chemical name] estra-1-, 3-, and 5(10)-triene-3,17-diol 3-benzoate, 17-[[4-[bis(2-chloroethyl)-amino]phenyl]-oxobutoxy] acetate. Development surveys show KM2210 is a benzoic acid ester derivative, developed since October 1987 for treating chronic lymphocytic leukemia (CLL). Phase III clinical validation results indicate better therapeutic effects on breast cancer and CLL. This drug is researched alongside hydroxyl doxorubicin and JM8 (carhop ugly tin), which are treatment progeria dementia drugs.
In the research and development unit Bristol Myers, JM-8 is a new substance formed by combining the ring structure of platinum complexes cisplatin and hydrocarbons. Cisplatin administration can lead to nephrotoxic side effects. JM-8 and CDDP have equal anti-tumor efficacy while alleviating KRN860 nephrotoxicity and gastrointestinal side effects.
Sankyo’s recombinant type, KRN-860, uses E. coli to produce a 174-cyano protein, which is an ideal anti-cancer drug. Clinical phase II began in February 1987 for bone marrow transplant granulocyte cell deficiency. By June 1989, phase I clinical validation was completed, and in spring 1990, the drug started being applied for lung cancer patients who experience granulocyte cell deficiency after chemotherapy. It also shows therapeutic effects on this condition.
Wong Chi Seng translated the section on azelaic cloud Military Academy Monthly pharmacy 1990’3 .2 (~ 209 41l204, (5): 1993 √. According to a Pharmaceutical Association survey, there are 11 pharmaceutical companies developing 16 new drugs for treating progeria dementia (Table 1). One drug is expected to be listed in 1990. Although it does not cure the disease, it represents an important step forward in mitigating the hazards affecting approximately four million Americans. Table 1 lists some drugs that block the action of enzymes destroying brain chemicals essential for transmitting important brain reactions. Elderly dementia patients lack this neurotransmitter acetylcholine. Inhibition of AChE density protects acetylcholine, helping Alzheimer’s patients prevent memory loss and memory disturbances.